Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients


LUND, Sweden, Feb. 26, 2022 /PRNewswire/ — Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix® (imlifidase) has been granted early access post marketing authorization (Autorisation d’accès précoce) in France by French HAS (Haute Autorité de Santé) for use in the desensitization of highly sensitized adult patients prior to kidney transplant, in accordance with the patient population specified in the Marketing Authorization received from the European Medicines Agency (EMA)

Read More

Next Post

10 Ways Yoga Can Improve Your Health

Intermountain’s yoga instructor, Adam Ballenger, at our Park City LiVe Well Center speaks to us on how yoga can improve your health. Adam uses his over 25 years of teaching yoga and his experience as an Exercise Therapist to help walk us through 10 ways you and I can use […]
Featured Video Play Icon